EST Oruka Therapeutics (ORKA) files to sell 8.72M shares of common stock for holders Published first on TheFly – the ultimate ...

Sam Slutsky’s rating is based on Oruka Therapeutics’ strong financial position and promising drug development pipeline. The company recently completed a reverse merger and has successfully raised over ...

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...

Previously as Chief Medical Officer at Vifor Pharma, Frits successfully led several assets through clinical development to ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

Jade Biosciences, Inc., a privately held biotechnology company dedicated to developing best-in-class therapies for patients ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

Jade's existing Board of Directors will remain in place, chaired by Eric Dobmeier, former President and CEO of Chinook Therapeutics and current Venture Partner at Samsara BioCapital. Board members ...